Back to companies

Sangamo Therapeutics Inc: Premium Databases

Sangamo Therapeutics Inc Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Sangamo Therapeutics Inc Insights data

Headline Published Journalists
Showing 3 of 30+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 15 Mar 2019 Lorem
Sangamo’s Phase I SB-913 study in MPS II unlikely to see neurological disease changes but somatic manifestations have better chance, experts say 17 Oct 2018 Mina Moawad
Sangamo’s gene therapy clinical development less appealing if hemophilia A trial repeats preclinical immunosuppression strategy, experts say 16 Mar 2018 Alaric DeArment
Sangamo’s next trial of MPS-1 gene therapy raises design challenges around patient variability, CNS measures and control arm -- experts 29 Jan 2018 Fiona Barry,;Hamish McDougall


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer